ImmunityBio's Anktiva wins conditional EMA approval, but faces stiff competition and financial risks. Click for why IBRX ...

A new drug developed at UC Davis Health could provide a safer and more effective option for bladder cancer patients, reducing chemotherapy toxicity and potentially limiting the need for bladder ...

An updated edition of the October 28, 2025, article. The global oncology market is entering a period of significant evolution, supported by rising cancer incidence and rapid scientific advancement.

Triage Plus was designed to detect mRNAs and DNA single-nucleotide variants from fibroblast growth factor receptor 3 and telomerase reverse transcriptase genes associated with bladder cancer.

Combination therapy with nogapendekin alfa inbakicept and BCG achieved a 3-year DSS rate of 96% in BCG-unresponsive NMIBC ...

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment ...

Following the positive outcome, Pfizer and Astellas will seek approval of Padcev-Keytruda in MIBC regardless of a patient’s ...

Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on ...

ImmunityBio Inc. (NASDAQ: IBRX) is one of the best multibagger penny stocks to buy right now. On December 12, analysts at ...

Harvey Risch, an epidemiologist respected for his cancer research, promoted the use of hydroxychloroquine during the pandemic ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...